COSCIENS Biopharma Inc. (LON: 0UGB)

Market Cap	8.55M
Revenue (ttm)	3.61M
Net Income (ttm)	-17.32M
Shares Out	n/a
EPS (ttm)	-10.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,235
Average Volume	211
Open	4.250
Previous Close	3.900
Day's Range	4.250 - 4.250
52-Week Range	2.166 - 5.581
Beta	n/a
RSI	42.17
Earnings Date	Mar 26, 2025

About COSCIENS Biopharma

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocr...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 12
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0UGB

Financial Performance

In 2023, COSCIENS Biopharma's revenue was $4.50 million, a decrease of -20.25% compared to the previous year's $5.64 million. Losses were -$16.55 million, -27.17% less than in 2022.

Financial numbers in USD